Search Ontology:
ChEBI
cidofovir anhydrous
- Term ID
- CHEBI:3696
- Synonyms
-
- (S)-(3-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
- (S)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine
- (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine
- (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine
- (S)-HPMPC
- ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
- 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine
- 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine
- [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
- CDV
- cidofovir
- Cidofovir anhydrous
- Definition
- Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.
- References
-
- Beilstein:5080484
- CAS:113852-37-2
- DrugBank:DB00369
- Drug_Central:639
- KEGG:C06909
- Patent:EP253412
- Patent:US5142051
- Wikipedia:Cidofovir
- Ontology
- ChEBI ( EBI )
- Resources
- CTD
- is a type of
-
- has_role
-
- inverse has_part
-
- inverse is_conjugate_base_of
-
- is_conjugate_acid_of
-
Phenotype
Phenotype resulting from cidofovir anhydrous
Phenotype where environments contain cidofovir anhydrous
Phenotype modified by environments containing cidofovir anhydrous
Human Disease Model